Extending the role of antithrombotic agents: An example based on the low-molecular-weight heparin, tinzaparin

Seminars in Thrombosis and Hemostasis

Volumn 30, Issue SUPPL. 1, 2004, Pages 3-9

  Hainer, James W ^a,b   Sprogel, Per ^c   Lindenstroem, Ewa ^c  

^a ASTRAZENECA   (United Kingdom)

^b AstraZcneca   (United States)

^c LEO PHARMA A S   (Denmark)

Author keywords

Cancer; Deep vein thrombosis; Heparin; LMWH; Low molecular weight heparin; Pharmacokinetics; Prophylaxis; Tinzaparin

Indexed keywords

ANTICOAGULANT AGENT; BLOOD CLOTTING FACTOR 10A; BLOOD CLOTTING FACTOR 11A; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; PLACEBO; TINZAPARIN;

ANGIOPLASTY; ANTICOAGULATION; BLEEDING; BRAIN HEMORRHAGE; CANCER; CANCER PATIENT; CARDIOVERSION; CHILD; CLINICAL TRIAL; CONFERENCE PAPER; DEEP VEIN THROMBOSIS; DOSE RESPONSE; DRUG EFFECT; DRUG HALF LIFE; EXPERIENCE; FEMALE; GASTROINTESTINAL HEMORRHAGE; HEART ATRIUM FIBRILLATION; HEMODIALYSIS; HIGH RISK POPULATION; HUMAN; KNEE ARTHROPLASTY; LUNG EMBOLISM; MALE; OBESITY; OUTPATIENT; PREGNANCY; PRIORITY JOURNAL; STROKE; THROMBOSIS; VENOUS THROMBOEMBOLISM;

FIBRINOLYTIC AGENTS; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; NEOPLASMS; THROMBOSIS;

EID: 1842608584     PISSN: 00946176     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2004-822998     Document Type: Conference Paper

References (45)

1. Fareed J, Jeske W, Hoppensteadt D, Clarizio R, Walenga JM. Low-molecular-weight heparins: pharmacologic profile and product differentiation. Am J Cardiol 1998;82:3L-10L
2. Linhardt RJ, Gunay NS. Production and chemical processing of low molecular weight heparins. Semin Thromb Hemost 1999;25(suppl 3):5-16
3. Bozarth J, Larnkjaer A, Johansen K, Mousa S. Plasmatic versus vascular effects of low molecular weight heparin (LMWH) on the release of tissue factor pathway inhibitor (TFPI) from human endothelial cells. In: XVIII Congress of the International Society on Thrombosis and Haemostasis, July 6-12,2001;Paris(abst 2056)
4. Mousa SA, Bozarth JM, Larnkjaer A, Johansen K. Vascular effects of heparin molecular weight fractions and low molecular weight heparins (LMWH) on the release of tissue factor pathway inhibitor (TFPI) from human endothelial cells. 2000;96(11):59b
5. Brieger D, Dawes J. Production method affects the pharmacokinetic and ex vivo biological properties of low molecular weight heparins. Thromb Haemost 1997;77:317-322
6. Fossler MJ, Barrett JS, Hainer JW, et al. Pharmacodynamics of intravenous and subcutaneous tinzaparin and heparin in healthy volunteers. Am J Health System Pharm 2001;58:1614-1621
7. Innohep Package Insert. Boulder, CO: Pharmion Corporation; 2002 June
8. Matzsch T, Bergqvist D, Hedner U, Østergaard P. Effects of an enzymatically depolymerized heparin as compared with conventional heparin in healthy volunteers. Thromb Haemost 1987;57:97-101
9. Pedersen PC, Østergaard PB, Hedner U, Bergqvist D, Matzsch T. Pharmacokinetics of a low molecular weight heparin, logiparin, after intravenous and subcutaneous administration to healthy volunteers. Thromb Res 1991;61:477-487
10. Barrett JS, Gibiansky E, Hull RD, et al. Population pharmacodynamics in patients receiving tinzaparin for the prevention and treatment of deep vein thrombosis. Int J Clin Pharmacol Ther 2001;39:431-446
11. Lassen MR, Borris LC, Christiansen HM, et al. Prevention of thromboembolism in 190 hip arthroplasties: comparison of LMW heparin and placebo. Acta Orthop Scand 1991;62:33-38
12. Planes A, Samama MM, Lensing AWA, et al. Prevention of deep vein thrombosis after hip replacement comparison between two low-molecular-weight heparins, tinzaparin and enoxaparin. Thromb Haemost 1999;81:22-25
13. Hull R, Rasob G, Pineo G, et al. A comparison of subcutaneous low-molecular-weight heparin with warfarin sodium for prophylaxis against deep-vein thrombosis after hip or knee implantation. N Engl J Med 1993;329:1370-1376
14. Matzsch T, Bergqvist D, Fredin H, Hedner U, Lindhagen A, Nistor L. Comparison of thromboprophylactic effect of a low molecular weight heparin versus dextran in total hip replacement. Thromb Haemorrh Disord 1991;3:25-29
15. Lassen MR, Borris LC, Jensen HP, et al. Prevention of thromboembolic complications after total hip arthroplasty: comparison of two different dosage regimens of tinzaparin. Thromb Haemost 1995;73:1104
16. Liezorovic A, Picolet H, Peyrieux JC, Boissel JP. Prevention of perioperative deep vein thrombosis in general surgery: a multicentre double blind study comparing two doses of logiparin and standard heparin. Br J Surg 1991;78:412-416
17. Jorgensen LN, Lausen I, Rasmussen MS, Wille-Jorgensen P, Bergqvist D. Prolonged thromboprophylaxis with low molecular weight heparin (tinzaparin) following major general surgery: an individual patient data meta-analysis. Blood 2002;100(11):501a
18. Marder VJ, Soulen RL. Quantitative venographic assessment of deep vein thrombosis in the evaluation of streptokinase and heparin therapy. J Lab Clin Med 1977;89:1018-1029
19. Breddin HK, Hach-Wunderle V, Nakov R, Kakkar VV. Effects of a low-molecular-weight heparin on thrombus regression and recurrent thromboembolism in patients with deep-vein thrombosis. N Engl J Med 2001;344:626-631
20. Siegbahn A, Hassan SY, Boberg J, et al. Subcutaneous treatment of deep venous thrombosis with low molecular weight heparin: a dose finding study with LMWH-Novo. Thromb Res 1989;55:767-778
21. Hull RD, Raskob GE, Pineo GF, et al. Subcutaneous low-molecular-weight heparin compared with continuous intravenous heparin in the treatment of proximal-vein thrombosis. N Engl J Med 1992;326:975-982
22. Green D, Hull Rd, Brant R, Pineo GF. Low mortality in cancer patients treated with low molecular-weight versus standard heparin (letter). Lancet 1992;339:1476
23. Valentine KA, Hull RD, Pineo GF. Low molecular-weight heparin therapy and mortality. Semin Thromb Hemost 1997;23:173-178
24. Simonneau G, Sors H, Charbonnier B, et al. A comparison of low-molecular-weight heparin with unfractionated heparin for acute pulmonary embolism. N Engl J Med 1991;337:663-669
25. The Columbus Investigators. Low-molecular-weight heparin in the treatment of patients with venous thromboembolism. N Engl J Med 1997;337:657-662
26. Koopmen MMW, Prandoni P, Piovella F, et al. Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. N Engl J Med 1996;334:682-687
27. Levine M, Gent M, Hirsh J, et al. A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis. N Engl J Med 1996;334:677-681
28. Hull Rd, Pineo GF, Mah AF, Brant RF. Home-liteL safety and efficacy results for a study investigating the lone-term out of hospital treatment of patients with proximal venous thrombosis using subcutaneous low-molecular- weight heparin versus warfarin. In: XVIII Congress of the International Society on Thrombosis and Haemostasis, July 6-12, 2001; Paris(abst OC1647)
29. Hainer JW, Barrett JS, Assaid CA, et al. Dosing in heavy-weight/obese patients with the LMWH, tinzaparin: a pharmacodynamic study. Thromb Haemost 2002;87:817-823
30. Hainer JW, Sherrard DJ, Swan SK, et al. Intravenous and subcutaneous weight-based dosing of the low molecular weight heparin tinzaparin (Innohep) in end-stage renal disease patients undergoing chronic hemodialysis. Am J Kidney Dis 2002;40:531-538
31. Siguret V, Pautas E, Fevrier M, et al. Elderly patients treated with tinzaparin (Innohep) administered once daily (175 anti-Xa IU/kg): anti-Xa and anti-IIa activities over 10 days. Thromb Haemost 2000;84:800-804
32. Smith MP, Norris LA, Stanley JL, et al. Innohep in pregnancy: a dose finding study of subcutaneous tinzaparin for thrombosis treatment and prevention during pregnancy. Blood 2000;96:694A
33. Monagle P, Michelson AD, Bovill E, Andrew M. Antithrombotic therapy in children. Chest 2001;119(suppl 1):344S-370S
34. Barrett JS, Mitchell DJ, Gastonguay M, Mitchell L, Andrew M. Forecasting anti-Xa activity in a pediatric dose finding trial with tinzaparin. In: XVIII Congress of the International Society on Thrombosis and Haemostasis, July 6-12, 2001; Paris(abst OC1647)
35. Kuhle S, Massicotte P, Andrew M, et al. A dose finding study of tinzaparin in pediatric patients. Blood 2002;100(11):279a
36. Bath PMW, Lindenstrom E, Boysen G, et al. Tinzaparin in acute ischaemic stroke (TAIST): a randomised aspirin-controlled trial. Lancet 2001;358:702-710
37. Cohen M, Demers C, Gurfinkel EP, et al. A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. N Engl J Med 1997;337:447-452
38. Antman EM, McCabe CH, Gurfinkel EP, et al. Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-q-wave myocardial infarction results of the Thrombolysis in Myocardial Infarction (TIMI)11B Trial. Circulation 1999;100:1593-1601
39. Young JJ, Kereiakes DJ. Low-molecular-weight heparin in percutaneous coronary intervention: ready for prime time? ACC Curr J Rev 2002;11(2):59-64
40. Ornstein DL, Zacharski LR. The use of heparin for treating human malignancies. Haemostasis 1999;29;(suppl 1):48-60
41. Amirkhosravi A, Francis J, Mousa S. Anti-metastatic effect of low molecular weight heparin (LMWH) tinzaparin and tissue factor pathway inhibitor (TFPI). In: XVIII Congress of the International Society on Thrombosis and Haemostasis, July 6-12, 2001;Paris(P1409 abst)
42. Mousa SA, Mohamed S. Anti-angiogenic efficacy and mechanism of the low molecular weight heparin (LMWH), tinzaparin and tissue factor pathway inhibitor (TFPI): potential anti-cancer link and benefits. In: XVIII Congress of the International Society on Thrombosis and Haemostasis, July 6-12, 2001;Paris(abst P1981)
43. Mousa SA, Bozarth J, Hainer JW, Sprogel P, Johansen K, Barrett JS. Pharmacodynamic effects of tinzaparin following 175 IU/kg subcutaneous administration in healthy volunteers on plasma tissue factor pathway inhibitor (TFPI). In: XVIII Congress of the International Society on Thrombosis and Haemostasis, July 6-12, 2001;Paris(abst P2299)
44. Chi YW, Dentoni S, Deitcher SR. Superficial venous thrombosis and subsequent cancer. In: XVIII Congress of the International Society on Thrombosis and Haemostasis, July 6-12; 2001; Paris (abst P1514)
45. Mousa SA, Bozarth JM. Inhibitory effect of C-reactive protein on the release of tissue factor pathway inhibitor from human endothelial cells: reversal by low molecular weight heparin. Blood 2002;100:498a